The trajectory of companies tied to flagship drugs like Viagra presents a complex investment scenario . While the initial boom of copyright, fueled by Viagra's extraordinary popularity, generated substantial returns, the patent expiration in key regions has introduced substantial risk . Investors are now grappling with the consequences of rival med